Return on Investment from the Prevention of Spinal Muscular Atrophy in Kuwait

Salem M. Abuhadida

doi:10.21601/ejeph/12321

Full Text (PDF)

Salem M. Abuhadida ¹ ^*

More Detail

¹ Health Economics Unit, Ministry of Health, KUWAIT^* Corresponding Author

Abstract

Background: Spinal muscular atrophy (SMA) is a rare genetic disease with a devastating nature and associated with significant clinical and economic burden. Fortunately, the availability of genetic screening and prevention technologies made preventive strategy possible. The aim of this study is to assess the return on investment from a prevention program that includes premarital genetic screening, preimplantation genetic diagnosis, and in vitro fertilization pertaining to SMA, spanning five-year period from the financial perspective of the Ministry of Health (MOH) in Kuwait.
Methods: A stochastic financial model was developed following a return on investment (ROI) approach spanning five-year period.
Results: An average ROI estimated to be 11% with cost saving amounted to 466,159 KWD (1,524,339 USD). The financial burden if the prevention program was not implemented is 16,441,539 KWD (53,763,832 USD).
Conclusion: This study is one of the very few in the region to estimate the benefits of implementing a prevention program pertaining to SMA from the financial perspective of the MOH in Kuwait.

Keywords

zolgensma
premarital genetic screening
preimplantation genetic diagnosis
in vitro fertilization
stochastic financial model

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Research Article

EUR J ENV PUBLIC HLT, Volume 6, Issue 2, 2022, Article No: em0120

https://doi.org/10.21601/ejeph/12321

Publication date: 09 Aug 2022

Article Views: 1216

Article Downloads: 737

Open Access References How to cite this article

References

Abuhadida, S., Bastaki, L., Bash, B. and Alhindal, B. (2022). Return on investment from the prevention of orphan diseases in Kuwait. Annals of Public Health. https://doi.org/10.55085/aph.2022.637
Armstrong, E. P., Malone, D. C., Yeh, W. S., Dahl, G. J., Lee, R. L. and Sicignano, N. (2016). The economic burden of spinal muscular atrophy. Journal of Medical Economics, 19(8), 822-826. https://doi.org/10.1080/13696998.2016.1198355
Bertram, M. Y., Lauer, J. A., Stenberg, K. and Edejer, T. (2021). Methods for the economic evaluation of health care interventions for priority setting in the health system: An update from WHO CHOICE. International Journal of Health Policy and Management, 10(11), 673-677. https://doi.org/10.34172/ijhpm.2020.244
Broekhoff, T. F., Sweegers, C., Krijkamp, E. M., et al. (2021). Early cost-effectiveness of onasemnogene abeparvovec-xioi (zolgensma) and nusinersen (spinraza) treatment for spinal muscular atrophy I in The Netherlands with relapse scenarios. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(6), 759-769. https://doi.org/10.1016/j.jval.2020.09.021
Cantoni, E. and Ronchetti, E. (2006). A robust approach for skewed and heavy-tailed outcomes in the analysis of health care expenditures. Journal of Health Economics, 25(2), 198-213. https://doi.org/10.1016/j.jhealeco.2005.04.010
Clementi, E. A., Talusan, A., Vaidyanathan, S., Veerappan, A., Mikhail, M., Ostrofsky, D., Crowley, G., Kim, J. S., Kwon, S. and Nolan, A. (2019). Metabolic syndrome and air pollution: A narrative review of their cardiopulmonary effects. Toxics, 7(1), 6. https://doi.org/10.3390/toxics7010006
Elmusharaf, K., Grafton, D., Jung, J. S., Roberts, E., et al. (2022). The case for investing in the prevention and control of non-communicable diseases in the six countries of the Gulf Cooperation Council: An economic evaluation. BMJ Global Health, 7(6), e008670. https://doi.org/10.1136/bmjgh-2022-008670
Gyngell, C., Stark, Z. and Savulescu, J. (2020). Drugs, genes and screens: The ethics of preventing and treating spinal muscular atrophy. Bioethics, 34(5), 493-501. https://doi.org/10.1111/bioe.12695
Hu, C., Zhou, H. and Sharma, A. (2020). Applying beta distribution in analyzing bounded outcome score data. The AAPS Journal, 22(3), 61. https://doi.org/10.1208/s12248-020-00441-4
Johannesson, M. and O’Conor, R. M. (1997). Cost-utility analysis from a societal perspective. Health Policy, 39(3), 241-253. https://doi.org/10.1016/s0168-8510(96)00878-0
Kolb, S. J. and Kissel, J. T. (2015). Spinal muscular atrophy. Neurologic Clinics, 33(4), 831-846. https://doi.org/10.1016/j.ncl.2015.07.004
Kuwait Times. (2019). SMA patients in Kuwait provided with world’s most expensive drug. Available at: https://storage.kuwaittimes.com/pdf/2019/nov/05/p01.pdf(Accessed 4 June 2022).
Le Magueresse-Battistoni, B., Vidal, H. and Naville, D. (2018). Environmental pollutants and metabolic disorders: The multi-exposure scenario of life. Frontiers in Endocrinology, 9, 582. https://doi.org/10.3389/fendo.2018.00582
Mulhern, B., Bansback, N., Brazier, J., Buckingham, K., et al. (2014). Preparatory study for the revaluation of the EQ-5D tariff: Methodology report. Health Technology Assessment, 18(12), vii-191. https://doi.org/10.3310/hta18120
Mulhern, B., Shah, K., Janssen, M. F., Longworth, L. and Ibbotson, R. (2016). Valuing health using time trade-off and discrete choice experiment methods: Does dimension order impact on health state values? Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 19(2), 210-217. https://doi.org/10.1016/j.jval.2015.11.005
National Council on Disability. (2019). “Quality adjusted life years and the devaluation of life with disability” report. Available at: https://ncd.gov/sites/default/files/NCD_Quality_Adjusted_Life_Report_508.pdf (Accessed 4 June 2022).
Nuijten, M. (2021). Pricing zolgensma–the world’s most expensive drug. Journal of Market Access & Health Policy, 10(1), 2022353. https://doi.org/10.1080/20016689.2021.2022353
Partnership to Improve Patient Care. (2017). Uses and misuses of the QALY: Ethical issues with qalys and alternative measures of value. Available at: http://www.pipcpatients.org/uploads/1/2/9/0/12902828/pipc_summary_-_uses_and_misuses_of_the_qaly.pdf (Accessed 4 June 2022).
Pioneer Institute. (2020). Quality adjusted life years (QALY): The threat to older Americans. Available at: https://pioneerinstitute.org/wp-content/uploads/dlm_uploads/QALYcovid-PB.pdf (Accessed 4 June 2022).
Prior, T. W. and Professional Practice and Guidelines Committee. (2008). Carrier screening for spinal muscular atrophy. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 10(11), 840-842. https://doi.org/10.1097/GIM.0b013e318188d069
Robinson, R. (1993). Cost-utility analysis. BMJ, 307(6908), 859-862. https://doi.org/10.1136/bmj.307.6908.859
Rouh AlDeen, N., Osman, A. A., Alhabashi, M. J., Al Khaldi, R., et al. (2021). The prevalence of β-thalassemia and other hemoglobinopathies in Kuwaiti premarital screening program: An 11-year experience. Journal of Personalized Medicine, 11(10), 980. https://doi.org/10.3390/jpm11100980
Schacht, R. M. (1980). Two models of population growth. American Anthropologist, 82(4), 782-798. https://doi.org/10.1525/aa.1980.82.4.02a00040
Schwarz, P. E., Reimann, M., Li, J., Bergmann, A., Licinio, J., Wong, M. L. and Bornstein, S. R. (2007). The metabolic syndrome–a global challenge for prevention. Hormone and Metabolic Research=Hormon-und Stoffwechselforschung=Hormones et metabolisme, 39(11), 777-780. https://doi.org/10.1055/s-2007-990312
Shawky, R. M. and El-Sayed, N. S. (2011). Clinico-epidemiologic characteristics of spinal muscular atrophy among Egyptians. Egyptian Journal of Medical Human Genetics, 12(1), 25-30. https://doi.org/10.1016/j.ejmhg.2011.02.015
US Food and Drug Administration. (2019). Package insert–zolgensma. Available aT: https://www.fda.gov/media/126109/download (Accessed 4 June 2022).
Verhaart, I., Robertson, A., Wilson, I. J., Aartsma-Rus, A., et al. (2017). Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy–a literature review. Orphanet Journal of Rare Diseases, 12(1), 124. https://doi.org/10.1186/s13023-017-0671-8
Xie, F., Gaebel, K., Perampaladas, K., Doble, B. and Pullenayegum, E. (2014). Comparing EQ-5D valuation studies: A systematic review and methodological reporting checklist. Medical Decision Making: An International Journal of the Society for Medical Decision Making, 34(1), 8-20. https://doi.org/10.1177/0272989X13480852

How to cite this article

Vancouver

Abuhadida SM. Return on Investment from the Prevention of Spinal Muscular Atrophy in Kuwait. EUR J ENV PUBLIC HLT. 2022;6(2):em0120. https://doi.org/10.21601/ejeph/12321

APA

Abuhadida, S. M. (2022). Return on Investment from the Prevention of Spinal Muscular Atrophy in Kuwait. European Journal of Environment and Public Health, 6(2), em0120. https://doi.org/10.21601/ejeph/12321

AMA

Abuhadida SM. Return on Investment from the Prevention of Spinal Muscular Atrophy in Kuwait. EUR J ENV PUBLIC HLT. 2022;6(2), em0120. https://doi.org/10.21601/ejeph/12321

Chicago

Abuhadida, Salem M.. "Return on Investment from the Prevention of Spinal Muscular Atrophy in Kuwait". European Journal of Environment and Public Health 2022 6 no. 2 (2022): em0120. https://doi.org/10.21601/ejeph/12321

Harvard

Abuhadida, S. M. (2022). Return on Investment from the Prevention of Spinal Muscular Atrophy in Kuwait. European Journal of Environment and Public Health, 6(2), em0120. https://doi.org/10.21601/ejeph/12321

MLA

Abuhadida, Salem M. "Return on Investment from the Prevention of Spinal Muscular Atrophy in Kuwait". European Journal of Environment and Public Health, vol. 6, no. 2, 2022, em0120. https://doi.org/10.21601/ejeph/12321